Getting it Right in Crohn’s Disease: A Clinical Guideline and Decision Tool-Based Approach (part 2 of 2)

Activity Overview

Despite evidence supporting usefulness of patient-specific risk stratification and personalized treatment, many patients with Crohn’s disease continue to be undertreated. In this activity, learners will explore new and available tools to help risk stratify patients with Crohn’s disease, predict the likelihood of response to various biologic therapies, and select appropriate treatment using these tools and AGA guidelines and care pathways. This activity provides tool demonstrations, video commentary, and case presentations all in one interactive, self-paced infographic.

0.25 CE Credit(s)
Expires: April 21, 2023

Target Audience

Gastroenterologists and primary care clinicians involved in the care of patients with inflammatory bowel disease (IBD).

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Employ standards of care for the management of inflammatory bowel disease (IBD) as presented in current guidelines
  • Apply IBD clinical decision support tools to risk stratify patients and aid in therapeutic selection
  • Select IBD therapies based on risk stratification and guideline recommendations

Activity Faculty

Dulai

Parambir S. Dulai, MD

Associate Professor, Medicine
Director, GI Clinical Trials
Director, Precision Medicine
Division of Gastroenterology & Hepatology
Feinberg School of Medicine, Northwestern University
Evanston, IL

Corey Siegel MD

Corey A. Siegel, MD, MS

Professor of Medicine and of The Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-Director, IBD Center
Dartmouth-Hitchcock Medical Center
Hanover, NH

Provider Statement

This activity is provided by AGA. Produced in collaboration with RMEI Medical Education, LLC.

Supporter Statement

This activity is supported by educational grants from Takeda Pharmaceuticals, U.S.A., Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources